The White House is taking on what it views as anticompetitive behavior by some generic drug companies that stave off additional generic entrants by being first to file and then “parking” exclusivity by failing to market their product. Cracking down on this practice will save the government $1.78 billion between 2019 and 2028, according to the White House's fiscal 2019 budget, released Monday (Feb. 12). Under the newly released budget, the White House proposes allowing FDA to tentatively approve a...